mAb Beta-29
An anti-SARS-CoV-2 monoclonal antibody.
General information
mAb Beta-29 is a monoclonal antibody neutralizing SARS-CoV-2 identified in a memory B cell of a COVID-19 convalescent patient who had been infected with the Beta variant of SARS-CoV-2 (Liu et al., 2022). mAb Beta-29 neutralizes Omicron variant in vitro (Dejnirattisai et al., 2022). It also neutralizes the Gamma variant but has reduced or no activity against the strains Alpha and Delta (is K417N/T-dependent) (Liu et al., 2022).
Synonyms
mAb β29
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Spike protein ACE2 RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
sera from vaccinated or convalescent individuals; VeroE6/TMPRSS2 cells; SARS-CoV-2 (various strains) | 41.58 | Neutralizes Omicron variant in vitro. |
Jan/04/2022 |
|
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Spike protein Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism Antibody Screening |
in vitro biophysical assay; crystallization; cryo-EM; plasma of COVID-19 (Beta strain) convalescent patients; Vero cells; VeroE6/TMPRSS2 cells; Vero-hACE2-TMPRSS2 cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (various strains) | 21.02 | Besides the Beta variant of SARS-CoV-2 the antibody also neutralizes the Gamma variant but has reduced or no activity against the strains Alpha and Delta (is K417N/T-dependent). |
Nov/27/2021 |
